Percutaneous coronary intervention with adjunctive abciximab and clopidogrel in a patient with chronic idiopathic thrombocytopaenic purpura

International Journal of Cardiovascular Interventions

Volumn 4, Issue 1, 2001, Pages 35-38

  Segal, O R ^a   Baker, C S R ^a   Banim, S ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Abciximab; Clopidogrel; Idiopathic thrombocytopaenic purpura; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DEVICE; DRUG SAFETY; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 0034859462     PISSN: 14628848     EISSN: None     Source Type: Journal    
DOI: 10.1080/146288401316922670     Document Type: Article

References (9)

1. Coronary artery bypass grafting in immune thrombocytopenic purpura
2. Primary percutaneous transluminal coronary angioplasty performed for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura
3. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease
4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting
5. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
6. Thrombotic thrombocytopenic purpura associated with clopidogrel
7. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans
8. Use of rapid platelet function analysis (RPFA) to evaluate platelet function in patients receiving incremental bolus dosing of abciximab during percutaneous coronary intervention (PCI)